Walker R A, Gullick W J, Varley J M
Department of Pathology, Leicester Royal Infirmary, UK.
Br J Cancer. 1989 Sep;60(3):426-9. doi: 10.1038/bjc.1989.299.
Eighty-five breast carcinomas from the same number of patients have been assessed immunohistochemically using the antiserum 21N for the presence of the c-erbB-2 protein. Twenty-two of the patients had evidence of advanced disease (tumour fixation or distant metastases) at presentation. Follow-up was for a median of 24 months. c-erbB-2 protein was detected in the majority of cells in 14 (16.5%) carcinomas, and to a lesser extent in a further six (7%) tumours. There was no relationship between staining and stage, node status or size but more poorly differentiated carcinomas had evidence of staining (36%) than well (17%) or moderately (14%) differentiated carcinomas (P = 0.02). There was a significant association between staining and mortality (P = 0.009) and recurrence (P = 0.0002). The relative risk of death for staining compared to no staining (after adjusting for node status, stage and grade) was 2.97 (95% confidence interval 1.29, 6.84) and the relative risk of recurrence for staining compared to no staining after similar adjustment was 3.85 (95% confidence interval 1.86-7.97). In this particular group of patients immunoreactivity for c-erbB-2 protein is an independent indicator of poor short-term prognosis.
对来自相同数量患者的85例乳腺癌进行了免疫组织化学评估，使用抗血清21N检测c-erbB-2蛋白的存在。22例患者在就诊时已有晚期疾病证据（肿瘤固定或远处转移）。随访时间中位数为24个月。在14例（16.5%）癌组织的大多数细胞中检测到c-erbB-2蛋白，另有6例（7%）肿瘤中检测到的程度较低。染色与分期、淋巴结状态或肿瘤大小之间无相关性，但低分化癌的染色阳性率（36%）高于高分化（17%）或中分化（14%）癌（P = 0.02）。染色与死亡率（P = 0.009）和复发（P = 0.0002）之间存在显著关联。与未染色相比，染色的相对死亡风险（在调整淋巴结状态、分期和分级后）为2.97（95%置信区间1.29, 6.84），在进行类似调整后，染色的相对复发风险为3.85（95%置信区间1.86 - 7.97）。在这组特定患者中，c-erbB-2蛋白的免疫反应性是短期预后不良的独立指标。
